Polar Asset Management Partners Inc. Sells 68,800 Shares of Omeros Corporation $OMER

Polar Asset Management Partners Inc. lessened its position in shares of Omeros Corporation (NASDAQ:OMER) by 25.6% during the first quarter, Holdings Channel reports. The institutional investor owned 200,000 shares of the biopharmaceutical company’s stock after selling 68,800 shares during the quarter. Polar Asset Management Partners Inc.’s holdings in Omeros were worth $2,112,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. International Assets Investment Management LLC increased its holdings in Omeros by 16.0% in the 1st quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 800 shares during the last quarter. Farther Finance Advisors LLC increased its stake in shares of Omeros by 16.5% in the fourth quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares in the last quarter. State of Wyoming bought a new stake in shares of Omeros in the fourth quarter valued at approximately $25,000. AQR Capital Management LLC raised its position in shares of Omeros by 7.2% in the fourth quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock valued at $392,000 after purchasing an additional 1,532 shares during the period. Finally, ProShare Advisors LLC boosted its holdings in Omeros by 12.1% in the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after buying an additional 1,637 shares during the period. Institutional investors own 48.79% of the company’s stock.

Insiders Place Their Bets

In other Omeros news, Director Thomas J. Cable sold 7,500 shares of the firm’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $11.61, for a total value of $87,075.00. Following the sale, the director owned 35,067 shares of the company’s stock, valued at $407,127.87. This trade represents a 17.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.50% of the stock is owned by corporate insiders.

Omeros Stock Performance

Omeros stock opened at $11.34 on Tuesday. The stock has a market cap of $820.73 million, a P/E ratio of 16.20 and a beta of 2.55. Omeros Corporation has a fifty-two week low of $3.43 and a fifty-two week high of $17.65. The firm’s fifty day moving average price is $10.26 and its 200-day moving average price is $11.46.

Omeros (NASDAQ:OMER) last issued its quarterly earnings data on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.16. The business had revenue of $9.89 million during the quarter, compared to analysts’ expectations of $4.19 million. Sell-side analysts predict that Omeros Corporation will post -0.94 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on OMER shares. Weiss Ratings lowered Omeros from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 2nd. D. Boral Capital reiterated a “buy” rating and set a $36.00 price objective on shares of Omeros in a research note on Tuesday, April 21st. Wall Street Zen cut Omeros from a “buy” rating to a “hold” rating in a report on Sunday, June 7th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Omeros in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.